Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tigilanol tiglate by QBiotics Group for Soft Tissue Sarcoma: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase II for Soft Tissue Sarcoma. According to...
Tigilanol tiglate by QBiotics Group for Breast Cancer: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Breast Cancer. According to GlobalData,...
Tigilanol tiglate by QBiotics Group for Squamous Cell Carcinoma: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Squamous Cell Carcinoma. According to...
Tigilanol tiglate by QBiotics Group for Fibrosarcoma: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase II for Fibrosarcoma. According to GlobalData, Phase...
Tigilanol tiglate by QBiotics Group for Merkel Cell Carcinoma: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Merkel Cell Carcinoma. According to...
Tigilanol tiglate by QBiotics Group for Adenocarcinoma: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Adenocarcinoma. According to GlobalData, Phase...
Tigilanol tiglate by QBiotics Group for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Basal Cell Carcinoma (Basal Cell...
Tigilanol tiglate by QBiotics Group for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According...